RNAC Earnings & Financial Statements
Cartesian Therapeutics, Inc.
$6.82
+$0.14(+2.10%)
33
Overall
40
Value
30
Tech
31
Quality
Market Cap
$202.11M
Volume
214.39K
52W Range
$5.60 - $11.00
Target Price
$33.67
RNAC earnings and financial statements: Cartesian Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RNAC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.80M | $38.91M | $26.00M | $110.78M | $85.08M |
| Operating income | -$143.41M | -$43.90M | -$86.42M | $14.54M | -$4.60M |
| EBITDA | -$135.76M | -$73.55M | -$234.01M | $40.05M | -$5.63M |
| Net income | -$130.30M | -$77.42M | -$219.71M | $35.38M | -$25.69M |
| EPS (diluted) | $-5.02 | $-4.49 | $-49.80 | $3.00 | $-6.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $296.41M | $435.02M | $305.05M | $165.89M | $159.88M |
| Total liabilities | $422.65M | $441.82M | $444.68M | $72.06M | $137.36M |
| Shareholders’ equity | -$126.24M | -$6.80M | -$440.18M | $93.83M | $22.52M |
| Cash and equivalents | $125.14M | $212.61M | $76.91M | $106.44M | $114.06M |
| Long-term debt | $8.53M | $11.13M | $8.79M | $27.84M | $28.27M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$73.94M | -$23.67M | -$51.16M | -$31.63M | -$60.38M |
| Capital expenditure | -$5.45M | -$8.74M | -$206.0K | -$1.20M | -$1.08M |
| Free cash flow | -$79.39M | -$32.77M | -$51.37M | -$32.83M | -$61.47M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RNAC | $6.82 | +2.1% | 214.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cartesian Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW